These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 8018385)
1. Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain. Zwart G; Back NK; Ramautarsing C; Valk M; van der Hoek L; Goudsmit J AIDS Res Hum Retroviruses; 1994 Mar; 10(3):245-51. PubMed ID: 8018385 [TBL] [Abstract][Full Text] [Related]
2. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas. Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630 [TBL] [Abstract][Full Text] [Related]
3. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides. Vogel T; Kurth R; Norley S J Immunol; 1994 Aug; 153(4):1895-904. PubMed ID: 7519220 [TBL] [Abstract][Full Text] [Related]
4. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993. Sherefa K; Sällberg M; Sönnerborg A AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097 [TBL] [Abstract][Full Text] [Related]
5. Characterization of the specificity of the human antibody response to the V3 neutralization domain of HIV-1. Zwart G; Wolfs TF; Valk M; Van der Hoek L; Kuiken CL; Goudsmit J AIDS Res Hum Retroviruses; 1992 Nov; 8(11):1897-908. PubMed ID: 1489578 [TBL] [Abstract][Full Text] [Related]
6. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. Vancott TC; Polonis VR; Loomis LD; Michael NL; Nara PL; Birx DL AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1379-91. PubMed ID: 8573396 [TBL] [Abstract][Full Text] [Related]
7. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression. Zwart G; van der Hoek L; Valk M; Cornelissen MT; Baan E; Dekker J; Koot M; Kuiken CL; Goudsmit J Virology; 1994 Jun; 201(2):285-93. PubMed ID: 7514319 [TBL] [Abstract][Full Text] [Related]
8. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection. Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041 [TBL] [Abstract][Full Text] [Related]
9. Pattern of antibody response against the V3 loop in children with vertically acquired immunodeficiency virus type 1 (HIV-1) infection. De Rossi A; Zanotto C; Mammano F; Ometto L; Del Mistro A; Chieco-Bianchi L AIDS Res Hum Retroviruses; 1993 Mar; 9(3):221-8. PubMed ID: 7682425 [TBL] [Abstract][Full Text] [Related]
10. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1. Krachmarov CP; Kayman SC; Honnen WJ; Trochev O; Pinter A AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1737-48. PubMed ID: 11788025 [TBL] [Abstract][Full Text] [Related]
11. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Kang CY; Luo L; Wainberg MA; Li Y Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338 [TBL] [Abstract][Full Text] [Related]
12. Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity. Warren RQ; Anderson SA; Nkya WM; Shao JF; Hendrix CW; Melcher GP; Redfield RR; Kennedy RC J Virol; 1992 Sep; 66(9):5210-5. PubMed ID: 1380094 [TBL] [Abstract][Full Text] [Related]
13. Peptide serology for analysis of the inter- and intra-individual variation in the HIV-1 V3 domain. Jansson M; Wahren B; Albert J; Scarlatti G; Franzén L; Kataaha PK; Katabira E; Mubiro F; Wigzell H; Rossi P AIDS; 1994 Apr; 8(4):413-21. PubMed ID: 8011244 [TBL] [Abstract][Full Text] [Related]
14. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency. Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728 [TBL] [Abstract][Full Text] [Related]
15. Anti-V3 antibody reactivity correlates with clinical stage of HIV-1 infection and with serum neutralizing activity. Fenouillet E; Blanes N; Benjouad A; Gluckman JC Clin Exp Immunol; 1995 Mar; 99(3):419-24. PubMed ID: 7533680 [TBL] [Abstract][Full Text] [Related]
16. Fine specificity of antibody recognition may predict amino acid substitution in the third variable region of gp120 during HIV type 1 infection. Langedijk JP; Zwart G; Goudsmit J; Meloen RH AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1153-62. PubMed ID: 8573370 [TBL] [Abstract][Full Text] [Related]
17. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies. Beddows S; Louisirirotchanakul S; Cheingsong-Popov R; Easterbrook PJ; Simmonds P; Weber J J Gen Virol; 1998 Jan; 79 ( Pt 1)():77-82. PubMed ID: 9460926 [TBL] [Abstract][Full Text] [Related]
18. Lack of autologous neutralizing antibodies in the cerebrospinal fluid of HIV-1 infected individuals. von Gegerfelt A; Chiodi F; Keys B; Norkrans G; Hagberg L; Fenyö EM; Broliden K AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1133-8. PubMed ID: 1503825 [TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers. Rubinstein A; Goldstein H; Pettoello-Mantovani M; Mizrachi Y; Bloom BR; Furer E; Althaus B; Que JU; Hasler T; Cryz SJ AIDS; 1995 Mar; 9(3):243-51. PubMed ID: 7755912 [TBL] [Abstract][Full Text] [Related]
20. The HIV-1 V3 domain on field isolates: participation in generation of escape virus in vivo and accessibility to neutralizing antibodies. Arendrup M; Akerblom L; Heegaard PM; Nielsen JO; Hansen JE Arch Virol; 1995; 140(4):655-70. PubMed ID: 7794110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]